FOLD - Amicus up 6% premarket on preliminary Q3 results October, 10 2019 09:01 AM Amicus Therapeutics Inc. Amicus Therapeutics (NASDAQ:FOLD) expects Galafold sales in Q3 to be ~$48M, up 133% from a year ago and above consensus of ~$45M.More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...